In the face of escalating antibiotic resistance, Kinvard Bio is pioneering a new frontier in the development of new antibiotics for drug-resistant infections.This innovative startup, emerging from Harvard's Myers Lab, is focused on creating novel compounds that tackle infections caused by resilient bacteria.